Approach to Resectable Biliary Cancers.

Area of Science:

• Surgical Oncology
• Gastrointestinal Surgery
• Hepatobiliary Surgery

Background:

• Biliary malignancies, including intrahepatic cholangiocarcinoma, hilar cholangiocarcinoma, distal cholangiocarcinoma, and gallbladder carcinoma, present unique surgical challenges.
• Resectability is a key determinant in the management strategy for these rare but complex tumors.

Purpose of the Study:

• To outline current surgical and adjuvant treatment strategies for various biliary tract cancers.
• To delineate the indications for specific surgical resections and the role of neoadjuvant and adjuvant chemotherapy.

Main Methods:

• Management strategies are based on tumor location (intrahepatic, hilar, distal) and type (gallbladder carcinoma).
• Surgical approaches include anatomic resection, non-anatomic resection, extended hepatectomy, caudate resection, and pancreaticoduodenectomy.
• Chemotherapy decisions (neoadjuvant vs. adjuvant) are guided by resectability, nodal status, and margin involvement.

Main Results:

• Intrahepatic cholangiocarcinomas are managed with anatomic resection for centrally located/multiple tumors and non-anatomic resection for solitary peripheral tumors.
• Hilar cholangiocarcinomas require extended hepatectomy with caudate resection for resectable cases.
• Distal cholangiocarcinomas are treated with pancreaticoduodenectomy, and gallbladder carcinoma with radical cholecystectomy and segment IVb/V resection.
• Adjuvant chemotherapy is indicated for nodal involvement, positive margins (R1), and T2 or higher gallbladder cancers.

Conclusions:

• Surgical resection remains the cornerstone for resectable biliary tract cancers.
• Adjuvant chemotherapy is crucial for improving outcomes in cases with adverse pathological features.
• Neoadjuvant chemotherapy is not routinely employed but may be considered in specific contexts like clinical trials for unresectable disease.